FDA granted accelerated approval to GSK’s Nelkarmi (neladalkib) on Nov 17, 2026 for pretreated ALK positive lung cancer, with 49% response after alectinib.
Last updated: November 18, 2026
The FDA granted accelerated approval to GSK’s Nelkarmi (neladalkib), a once daily ALK selective pill, for adults with advanced ALK positive non small cell lung cancer after alectinib, or after two or more ALK inhibitors plus platinum chemotherapy. It landed ten days before its November 27 target date.
Scope: what was approved, the ALKOVE-1 data behind it, the label’s safety picture, and what it means for GSK, prescribers and the ALK field. Sources are GSK’s November 17 release and the US prescribing information.
What did the FDA approve on November 17, 2026?
The FDA approved Nelkarmi (neladalkib) under accelerated approval for adults with locally advanced or metastatic ALK positive non small cell lung cancer (NSCLC) who have already been treated in the advanced setting with either one prior ALK tyrosine kinase inhibitor (TKI), specifically alectinib, or two or more prior ALK TKIs plus platinum based chemotherapy.
GSK announced the decision on November 17 and said it came ahead of the original FDA target action date of November 27, 2026. By our count that is ten days early. The drug carried Breakthrough Therapy and Orphan Drug designations. The label states the indication is approved under accelerated approval based on tumor response rate and duration of response, and that continued approval may depend on a confirmatory trial verifying clinical benefit.
Nelkarmi is GSK’s second lung cancer approval of 2026. The first was Jideytro (zidesamtinib) for previously treated ROS1 positive NSCLC in July. Both came from GSK’s acquisition of Nuvalent, Inc., which GSK completed this year.
How well did neladalkib work in ALKOVE-1?
In the single arm Phase I/II ALKOVE-1 trial (NCT05384626), confirmed response rate by blinded independent central review was 49% in patients whose only prior ALK inhibitor was alectinib and 32% in patients who had cycled through two or more ALK inhibitors plus chemotherapy.
ALKOVE-1 enrolled 700 patients with ALK positive solid tumors across both phases. The primary efficacy analysis that supports the approval covers 222 patients with previously treated ALK positive NSCLC. Here is how the two labeled groups break down.
| Measure (BICR) | Alectinib only prior | 2+ ALK TKIs plus chemo |
|---|---|---|
| Patients evaluated for response | 67 | 155 |
| Confirmed objective response rate | 49% (33/67; 95% CI 37% to 62%) | 32% (50/155; 95% CI 24% to 40%) |
| Responders lasting 6+ months | 76% | 69% |
| Responders lasting 12+ months | 52% | 51% |
| Intracranial response (measurable brain metastases) | 55% (11/20; 95% CI 32% to 77%), 25% complete | 26% (14/53; 95% CI 15% to 40%), 11% complete |
Source: GSK release, November 17, 2026. Table is ours.
The read: the after alectinib group is the commercial heart of the label. Alectinib has been a common first line ALK choice, so the patient who progresses on it is a large, recurring population. A response rate near half, with about half of those responses still holding at a year, is the number oncologists will anchor on. The heavily pretreated group responds less often, but when it does respond the durability is similar.
Why does brain penetration matter so much in ALK lung cancer?
NSCLC can often spread to the central nervous system, as GSK’s release notes, and patients who progress on one ALK inhibitor need a drug that still hits the tumor. GSK says neladalkib was designed for broad coverage of ALK resistance mutations, the ability to cross the blood brain barrier, and high target selectivity.
The intracranial data back the design claim in the alectinib only group: 11 of 20 patients with measurable brain metastases responded, and GSK reports complete responses at 25%. The pretreated group’s 26% intracranial rate is lower, and both CNS samples are small. Prescribers should read the brain data as encouraging, not definitive.
GSK’s chief scientific officer Tony Wood framed the patient profile directly: ALK positive patients are often younger and can remain on treatment for years. That makes tolerability a commercial variable, not just a clinical one.
What are the main safety risks on the Nelkarmi label?
Liver toxicity is the headline risk. In the pooled safety population of 700 patients, hepatotoxicity occurred in 56%, with grade 3 in 18% and grade 4 in 7%. There is no boxed warning.
The label lists five warnings and precautions: hepatotoxicity (including drug induced liver injury leading to hepatic failure), renal toxicity including acute kidney injury, ocular toxicity including retinal detachment, creatine phosphokinase elevation, and embryo fetal toxicity. Hepatotoxicity led to dose interruption in 25% of patients, dose reduction in 11% and permanent discontinuation in 3%.
Across all adverse reactions, GSK reports permanent discontinuation in 5% of patients. The most common reactions (20% or more) were hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema and fatigue.
| Label item | What it says |
|---|---|
| Dose | 150 mg orally once daily, with or without food |
| Dose reductions | 100 mg, then 50 mg; stop if 50 mg is not tolerated |
| Tablets | 50 mg and 150 mg |
| Boxed warning | None |
| Key interactions | Avoid strong or moderate CYP3A inhibitors and inducers |
| Patient selection | ALK rearrangement documented by local testing (NGS, PCR, FISH or IHC were used in the trial); no companion diagnostic named |
Source: Nelkarmi US prescribing information, revised 11/2026.
For operators, the practical consequence is monitoring. Liver and kidney labs, eye symptoms and CPK all need a plan, and the CYP3A interaction rule matters for patients on common concomitant drugs.
What does accelerated approval mean for Nelkarmi’s future?
Accelerated approval means the FDA accepted response rate and duration as reasonably likely to predict clinical benefit, and GSK must confirm that benefit. GSK names ALKAZAR, an ongoing Phase III trial in TKI naive ALK positive NSCLC, as the trial evaluating neladalkib in earlier disease.
The release does not give ALKAZAR’s comparator, enrollment or readout timing, so we won’t guess. The strategic point is clear: the real prize in ALK disease is first line, where patients stay on therapy longest. A second line approval puts Nelkarmi in prescribers’ hands now and builds real world experience before any first line data. For how confirmatory obligations work, see our accelerated approval explainer.
What does this mean for GSK and the ALK market?
For GSK, Nelkarmi is proof the Nuvalent deal is producing approvals on schedule. GSK’s third quarter filing shows Jideytro launched in the US in Q3 2026 with £3 million in sales, a small opening number that reflects a July launch. Nelkarmi gives the oncology sales force a second targeted lung product inside one year.
For the ALK field, the bar for later line therapy just moved. Earlier generation inhibitors such as crizotinib, alectinib, brigatinib and lorlatinib built the sequence that patients move through today. A drug labeled specifically for post alectinib disease, with brain activity and a 5% overall discontinuation rate, will be judged on whether its liver signal is manageable in routine practice. Pricing and launch timing were not disclosed in the release.
Our framework: five checks for any targeted oncology accelerated approval
- Read the indication word for word. Nelkarmi’s label names alectinib specifically. Patients who received a different single prior ALK TKI are not in that group.
- Split the response rate by prior therapy. 49% and 32% describe two different patient populations and two different markets.
- Pair response with durability. The share of responders past 12 months tells you more than the headline rate.
- Find the dominant toxicity and its management. Here it is liver: 56% any grade, but only 3% discontinued for it.
- Locate the confirmatory trial. If it is in an earlier line (ALKAZAR is TKI naive), it is both a regulatory obligation and the growth plan.
What to watch next
- Launch timing and US list price, neither disclosed on November 17.
- ALKAZAR design details and any readout guidance from GSK.
- Whether NCCN guidelines place Nelkarmi after alectinib progression, and how it is sequenced against lorlatinib.
- Jideytro’s first line ROS1 filing, which GSK lists as a planned US submission.
FAQ
What is Nelkarmi?
Nelkarmi is the brand name for neladalkib, an oral ALK selective tyrosine kinase inhibitor from GSK. It was developed by Nuvalent, which GSK acquired in 2026.
When was Nelkarmi approved?
GSK announced FDA accelerated approval on November 17, 2026, ten days ahead of the November 27 target action date.
Who is Nelkarmi approved for?
Adults with locally advanced or metastatic ALK positive NSCLC previously treated with alectinib as their only ALK inhibitor, or with two or more ALK inhibitors plus platinum chemotherapy.
What response rate did neladalkib show?
Confirmed objective response rate was 49% after alectinib only and 32% after two or more ALK inhibitors plus chemotherapy, by blinded independent central review in ALKOVE-1.
Does Nelkarmi work on brain metastases?
In patients with measurable brain metastases, intracranial response was 55% (11 of 20) after alectinib only and 26% (14 of 53) in the more pretreated group. Samples are small.
What is the Nelkarmi dose?
150 mg by mouth once daily with or without food, with reductions to 100 mg and then 50 mg for side effects.
Does Nelkarmi have a boxed warning?
No. The label has no boxed warning, but it lists hepatotoxicity, renal toxicity, ocular toxicity, CPK elevation and embryo fetal toxicity as warnings and precautions.
How common is liver toxicity with neladalkib?
In 700 patients, hepatotoxicity occurred in 56%, grade 3 in 18% and grade 4 in 7%. It led to permanent discontinuation in 3%.
Why is it an accelerated approval?
The approval rests on response rate and duration from a single arm trial. GSK must show clinical benefit in confirmatory work; ALKAZAR is the ongoing Phase III in TKI naive patients.
Is a companion diagnostic required?
The label does not name one. The trial used ALK rearrangement documented by local laboratories using NGS, PCR, FISH or IHC.
How much does Nelkarmi cost?
GSK did not disclose a price or launch date in its approval release.
Sources
- Primary: GSK plc, Nelkarmi (neladalkib) approved in the US for previously treated advanced ALK positive NSCLC, November 17, 2026.
- Primary: Nelkarmi US prescribing information, revised 11/2026.
- Primary: GSK plc Form 6-K, Q3 2026 results (Jideytro Q3 sales and launch; pipeline table).
- Not used: the Nuvalent deal value. Trade and filing summaries differ on the figure, so we left it out.
Related coverage
- SELLAS Phase 3 REGAL: 41% lower death risk in AML maintenance
- FDA accelerated approval: confirmatory trial rules explained
- PDUFA date explained: goal dates, extensions and early decisions
- Boxed warning vs warnings and precautions
- What is an oral SERD? ESR1 breast cancer drugs compared
- What is Project Orbis?
- BioMed Nexus company directory
Get the daily biotech, pharma and medtech briefing: subscribe to BioMed Nexus.


